Frontlight ResearchEarly access
Taking peopleNo phase
Accelerated Rotational Field Deep TMS for Treating OCD
Key facts
- Who runs it
- Ben-Gurion University of the Negev
- Where
- Israel1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 50 people, planned
- Started
- 19 Sept 2023
- Expected to end
- 14 Dec 2028
- Type of study
- Interventional, 2 groupsOne group gets a sham (pretend) treatment, for comparison.
- Treatments tested
- BrainsWay Deep TMS HAC/H7-Coil
- BrainsWay Deep TMS Sham Coil
- Record updated
- 12 August 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 29 criteriaShow less
Who can take part
- Outpatients
- Diagnosed as suffering from OCD according to the DSM-V
- Subjects with a YBOCS score of >20
- If on SRI, patient must be maintained on current dosages (with or without additional antidepressant or psychotropic augmentation for treatment of OCD), at a stable therapeutic dosage for at least 2 months prior to study entry and for the duration of the trial
- If in CBT, must be in the maintenance stage (i.e., not receiving active training in exposure and response prevention, which is the core component of this treatment). CBT can be with teletherapy but must be for a minimum of ten sessions with a symptom checklist, hierarchy, with exposure and response prevention therapy
- Have negative or justified responses by the investigator to all questions listed on the Transcranial Magnetic Stimulation Safety Screening questionnaire (TASS)
- According to the treating physician the subject is compliant with taking medication, if applicable
- Subject is capable and willing to provide informed consent and assent
- Willing and able to adhere to the treatment schedule
- All comorbid diagnoses have been stable for 3 months and anticipated to be stable for the 3 months treatment duration
Who cannot take part
- Increased risk of seizure for any reason, including prior diagnosis of increased intracranial pressure, or history of significant head trauma with loss of consciousness for greater than or equal to 5 minutes
- Subject on high doses of antidepressant or psychotropic medications, which are known to lower the seizure threshold. Subject is currently on Clomipramine
- Comorbid, secondary psychiatric diagnoses are unstable and are likely to require changes in therapeutic regimens even if OCD improves
- Present suicidal risk as assessed by the investigator using the Columbia Suicide Severity Rating Scale, brief mental status exam and psychiatric interview or a history of attempted suicide in the past year
- History of epilepsy or seizure (EXCEPT those therapeutically induced by ECT and febrile seizures in infancy)
- History of head injury necessitating cranial surgery or prolonged coma
- History of any ferromagnetic of conductive material in the head including the eyes and ears (outside the mouth)
- Known history of any metallic particles in the eye, implanted neurostimulators, intracranial implant (e.g., aneurysm clips, shunts, stimulators, cochlear implants, or electrodes)
- History of significant hearing loss
- Subjects with significant neurological disorder or insult
- Substance use disorder within the past 6 months (except nicotine and caffeine and based on the doctor's judgment)
- Suffer from an unstable physical, systemic and metabolic disorder such as unstable blood pressure, unstable blood sugar, or acute, unstable cardiac disease
- Subjects diagnosed as suffering from any other Axis I diagnosis as the primary diagnosis
- Currently participating in another therapeutic clinical study
- Significant possibility of death within eighteen months of baseline
- Planned surgeries that will interrupt the study schedule within four months of baseline
- Women who are breast-feeding
- Women who are pregnant or with suspected pregnancy
- Women of childbearing potential and not using a medically accepted form of contraception when engaging in sexual intercourse
This trial is currently available in Israel.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
A Prospective Double Blind Randomized Controlled Trial to Evaluate the Efficacy and Durability of the BrainsWay Rotational Field Deep Transcranial Magnetic Stimulation (Deep TMS) in Obsessive-Compulsive Subjects
The 2 groups in the trial
- Active TMSTreatment being tested
Treatment: BrainsWay Deep TMS HAC/H7-Coil
- Sham TMSSham treatment, for comparison
Treatment: BrainsWay Deep TMS Sham Coil
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Prospective Double Blind Randomized Controlled Trial to Evaluate the Efficacy and Durability of Accelerated BrainsWay Deep Transcranial Magnetic Stimulation (Deep TMS) Protocol in Obsessive-Compulsive Subjects
- Publications
- Distinct structural abnormalities in obsessive-compulsive and alcohol use disorders.European archives of psychiatry and clinical neuroscience, 2026
- Record updated
- 12 August 2025